Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
2021 · Leukemia · 109 citations
https://doi.org/10.1038/s41375-021-01125-4
M
Marco Cerrano
CTO Hospital(IT)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
136
Papers
1.5K
Citations
20
h-index
36
i10-index
Marco Cerrano is an academic researcher from CTO Hospital. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments & Acute Lymphoblastic Leukemia research. The author has an h-index of 20, co-authored 116 publications.
ORCID: 0000-0003-1666-3100Papers by this author
worksCPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
2020 · Blood Cancer Journal · 56 citations
https://doi.org/10.1038/s41408-020-00361-8
Can pegylated interferon improve the outcome of polycythemia vera patients?
2017 · Journal of Hematology & Oncology · 24 citations
https://doi.org/10.1186/s13045-017-0395-1
Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults
2022 · Leukemia · 18 citations
https://doi.org/10.1038/s41375-022-01671-5
Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges
2023 · Current Treatment Options in Oncology · 17 citations
https://doi.org/10.1007/s11864-023-01089-w
Characteristics and outcomes of patients with acute myeloid leukemia admitted to intensive care unit with acute respiratory failure: a post-hoc analysis of a prospective multicenter study
2023 · Annals of Intensive Care · 10 citations
https://doi.org/10.1186/s13613-023-01172-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat